Allegro reports Phase II Luminate data in vitreoretinal disease

Allegro Ophthalmics LLC (San Juan Capistrano, Calif.) said the highest of three Luminate ( ALG-1001) doses met the primary endpoint in a Phase II trial to treat vitreomacular traction (VMT) or vitreomacular adhesion (VMA).

The 106-patient study compared intavitreal injections of 2, 2.5 and 3.2 mg Luminate with placebo. Allegro said 65% of patients in the 3.2 mg group achieved release of VMT or VMA at 90 days vs. 9.7% of placebo patients (p=0.0129). The company said lower doses were not as effective. Allegro expects to have full study results by year end. ...